- Home
- GKOS vs DKNG Comparison
GKOS vs DKNG Comparison
Compare GKOS & DKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GKOS | DKNG |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | 1094 | N/A |
| Industry | Medical/Dental Instruments | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.5B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GKOS | DKNG |
|---|---|---|
| Price | $185.49 | $26.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 31 |
| Target Price | ★ $126.92 | $38.10 |
| AVG Volume (30 Days) | 855.1K | ★ 13.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.05 |
| EPS | N/A | ★ N/A |
| Revenue | $507,442,000.00 | ★ $6,054,525,000.00 |
| Revenue This Year | $23.32 | $15.47 |
| Revenue Next Year | $27.43 | $13.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.33 | 26.99 |
| 52 Week Low | $73.16 | $20.46 |
| 52 Week High | $189.69 | $48.78 |
Technical Indicators
Market Signals| Indicator | GKOS | DKNG |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 59.51 |
| Support Level | $99.75 | $23.69 |
| Resistance Level | N/A | $26.86 |
| Average True Range (ATR) | 7.77 | 1.07 |
| MACD | 1.39 | 0.36 |
| Stochastic Oscillator | 88.29 | 91.31 |
Price Performance
Historical ComparisonAbout GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. With its predictive market launch in 2025, DraftKings is now live with online or retail sports betting in most all states and i-gaming in five states, with both products available to around 40% of Canada's population. In 2025, sports revenue was 63% of total sales, i-gaming 30%, and fantasy and lottery 7%.